Literature DB >> 7030042

Primary heart disease in systemic sclerosis (scleroderma): advances in clinical and pathologic features, pathogenesis, and new therapeutic approaches.

G R Botstein, E C LeRoy.   

Abstract

Heart disease in SSCL may be primary or secondary. Primary involvement includes pericarditis, myocardial fibrosis, and contraction band necrosis with congestive cardiomyopathy, conduction system fibrosis, intramural coronary artery lesions and, rarely, valvular disease. Symptoms include those of left and right ventricular failure, chest pain, palpitations, syncope, and sudden death. Pathogenesis may be related to functional Raynaud's phenomenon of the heart and/or structural small vessel disease. Therapy at present is symptomatic; however, new therapeutic approaches are warranted.

Entities:  

Mesh:

Year:  1981        PMID: 7030042     DOI: 10.1016/0002-8703(81)90043-0

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  11 in total

Review 1.  Humoral immune response to cardiac conducting tissue.

Authors:  U Lotze; B Maisch
Journal:  Springer Semin Immunopathol       Date:  1989

2.  Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice.

Authors:  Dorothee Weihrauch; John G Krolikowski; Deron W Jones; Tahniyath Zaman; Omoshalewa Bamkole; Janine Struve; Paul S Pagel; Nicole L Lohr; Kirkwood A Pritchard
Journal:  J Vis Exp       Date:  2017-03-24       Impact factor: 1.355

3.  CREST syndrome with pericardial but not peripheral calcinosis.

Authors:  H G Taylor; P Sheldon; A J McCance; J D Skehan
Journal:  Ann Rheum Dis       Date:  1993-10       Impact factor: 19.103

4.  Left ventricular wall thickness and disease duration in systemic sclerosis.

Authors:  I Hegedüs; L Czirják
Journal:  Postgrad Med J       Date:  1993-04       Impact factor: 2.401

5.  Right-heart failure after right heart catheterization in a patient with scleroderma and suspected pulmonary hypertension.

Authors:  Gernot Keysser; Carola Schwerdt; Christiane Taege
Journal:  Rheumatol Int       Date:  2008-05-24       Impact factor: 2.631

6.  Pharmacodynamic effect of dipyridamole on thallium-201 myocardial perfusion in progressive systemic sclerosis with diffuse scleroderma.

Authors:  A Kahan; J Y Devaux; B Amor; C J Menkes; S Weber; J M Foult; A Venot; F Guerin; M Degeorges; J C Roucayrol
Journal:  Ann Rheum Dis       Date:  1986-09       Impact factor: 19.103

7.  Non-invasive assessment of early cardiac involvement in systemic sclerosis.

Authors:  G S Butrous; P M Dowd; J Milne; D S Dymond; J Caplin; A J Camm
Journal:  Postgrad Med J       Date:  1985-08       Impact factor: 2.401

8.  Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling.

Authors:  Laimute Taraseviciene-Stewart; Mark R Nicolls; Donatas Kraskauskas; Robertas Scerbavicius; Nana Burns; Carlyne Cool; Kathy Wood; Jane E Parr; Susan A Boackle; Norbert F Voelkel
Journal:  Am J Respir Crit Care Med       Date:  2007-04-05       Impact factor: 21.405

9.  An IRF5 Decoy Peptide Reduces Myocardial Inflammation and Fibrosis and Improves Endothelial Cell Function in Tight-Skin Mice.

Authors:  Dorothee Weihrauch; John G Krolikowski; Deron W Jones; Tahniyath Zaman; Omoshalewa Bamkole; Janine Struve; Savin Pillai; Paul S Pagel; Nicole L Lohr; Kirkwood A Pritchard
Journal:  PLoS One       Date:  2016-04-06       Impact factor: 3.240

10.  Cardiac magnetic resonance predicts ventricular arrhythmias in scleroderma: the Scleroderma Arrhythmia Clinical Utility Study (SAnCtUS).

Authors:  Sophie Mavrogeni; Luna Gargani; Alessia Pepe; Lorenzo Monti; George Markousis-Mavrogenis; Maria De Santis; Daniele De Marchi; Loukia Koutsogeorgopoulou; Georgia Karabela; Efthymios Stavropoulos; Gikas Katsifis; Konstantinos Bratis; Silvia Bellando-Randone; Serena Guiducci; Cosimo Bruni; Alberto Moggi-Pignone; Theodoros Dimitroulas; Genovefa Kolovou; Vasiliki-Kalliopi Bournia; Petros P Sfikakis; Marco Matucci-Cerinic
Journal:  Rheumatology (Oxford)       Date:  2020-08-01       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.